atherosclerosis, 3 among many others [T1] . While most such associations are controversial, these lines of research remain under active investigation. In this article, evidence for and against the association between late-onset Alzheimer's disease (AD) and persistent infection with C. pneumoniae will be reviewed.
AD is a progressive neurodegenerative disease associated with atrophy/ death of neurons in affected brain regions. The disease occurs in two forms: an early-onset form which is primarily genetically determined, and a far more common late-onset form which is not genetically determined. Incidence of the latter increases with increasing age, and AD is considered to be the most significant single cause of senile dementia. 4 The disease usually manifests itself in its early stages by minor loss of PCR assays from two groups indicated that C. pneumoniae DNA is present in a high proportion of brain tissue samples from late-onset Alzheimer's disease (AD) patients but not in those from non-AD controls.
̈Immunohistochemical analyses from two laboratories support this observation, and electron and immunoelectron microscopy have been used to visualize chlamydial organisms in the AD brain; however, some laboratories have been unable to repeat the PCR and immunohistochemical results.
Other experimental data support a relationship between the pathobiology of C. pneumoniae and possession of the APOE ε4 allele type, which is a known risk factor for late-onset AD.
memory and progresses to major cognitive dysfunction, which can include language difficulties, loss of orientation, and some behavioral disorders. 5 The rate of progression along the cognitive dysfunction pathway varies widely among affected individuals and can be as long as two decades or more. Death in late-onset AD patients occurs not from the disease itself, but rather from secondary causes. 5 The etiology underlying AD neuropathogenesis is poorly understood. The protein designated tau is a normal cytoskeletal component. Evidence suggests that its deposition in neurofibrillary tangles (NFT) results from aberrant post-translational modification or from unusual forms of the protein made by alternate splicing of its mRNA. 6 These aberrant forms of tau which form the NFT are thought to interfere with normal cytoskeletal formation in neurons, thereby contributing significantly to loss of those cells in the AD brain. Neuritic senile plaques (NSP) are comprised of β-amyloid (Aβ); deposition of this 39-42
amino acid peptide appears to be required for neuronal degeneration in AD, 7 although the mechanism by which this occurs is not fully understood. Aβ is derived from a region near the C-terminus of the amyloid precursor protein, which is encoded by the βAPP gene on chromosome 21. The normal function(s) of this large protein are unknown, but it is expressed in both neuronal and non-neuronal tissues. 7 My laboratory became interested in a possible relationship between bacterial infection and late-onset AD following discussions with Brian Balin, PhD, who described unsuccessful efforts to identify bacteria and viruses associated with the disease. After several false starts (ie, screening for organisms we did not find in AD brain tissue), a collaborative effort among my group, the Balin group, the JA Whittum-Hudson group, and others did identify C. pneumoniae in the late-onset AD brain. In hindsight, this organism probably should have been our initial focus, since many of its characteristics were appropriate to the studies we had undertaken.
Chlamydia pneumoniae
C. pneumoniae is an obligate intracellular bacterial parasite of eukaryotic cells.
Acquisition of all Chlamydia species is via mucosal surfaces. C. pneumoniae is a respiratory pathogen, and thus its initial sites of infection are the oral and nasal mucosa. 8 This organism is a significant agent in community-acquired pneumonia, 8 but studies have implicated C. pneumoniae in more severe pulmonary pathologies, including chronic obstructive pulmonary disease (COPD). 9 Infection with C. pneumoniae also has been associated with unexpected clinical entities, including arthritis 10 and atherosclerosis [T2]. 3, 11 In relation to the latter, in vitro studies show that C. pneumoniae infection induces foam cell formation and accumulation of cholesteryl esters within host cells, 12 providing biochemical evidence of a role for the organism in atherogenesis. Epidemiologic studies indicate that C. pneumoniae is ubiquitous. Prevalence of infection with the organism is high in all populations studied and appears to increase with increasing age. 8, 13 In one study, males 60 years and older showed a prevalence rate of 70%. 13 In crowded living conditions, childhood infection with C. pneumoniae is more common than in less densely populated regions. 13 Studies from Scandinavia indicate that epidemics of C. pneumoniae occur every 5-7 years, and that most individuals incur several infections over a lifetime. 8, 13 Initial Studies of C. pneumoniae in the Alzheimer's Brain
We developed polymerase chain reaction (PCR) assays targeting chromosomal DNA sequences of C. pneumoniae 10 and used them to assess DNA preparations from frozen brain autopsy tissues from 19 lateonset AD and an equal number of non-AD control patients. As described in the initial publication, 14 samples from brain areas showing characteristic neuropathology were PCR-positive for the organism in 17/19 AD patients in repeated assays; only one sample from an age-matched, non-AD control patient was positive. Electron microscopy (EM) to visualize the organism in AD brain samples revealed that areas of the hippocampus, temporal cortex, and/or other regions of AD brains with NFT and NSP contained objects that resembled C. pneumoniae, as well as chlamydial inclusions. We could identify no similar structures in non-AD control brains in parallel analyses. Immunoelectron microscopy (IEM) using a monoclonal antibody (mAb) targeting the major outer membrane protein (MOMP) of C. pneumoniae identified the objects resembling chlamydiae as authentic C. pneumoniae. Parallel examination of brain tissue sections from PCR-negative patients showed no labeling (ref. 14 for extensive controls and discussion).
For immunostaining of tissues from affected AD brain regions and congruent regions from non-AD brains, we used two mAb: a genus-specific mAb targeting the lipopolysaccharide (LPS) of Chlamydiae and the C. pneumoniae-specific anti-MOMP mAb. In sections from AD brains, we found staining in perivascular regions of blood vessels in the neuropil and in microglia-and astroglia-like cells not adjacent to such vessels; no labeling was seen with either mAb in brain sections from non-AD patients. We confirmed these cell types 14 Thus, chlamydia-infected astroglia and microglia in the late-onset AD brain are concentrated in regions of characteristic neuropathology.
To determine whether the identified C. pneumoniae were viable, we cultured the organism from homogenates of AD and control brains using the human monocyte cell line THP-1 as host. Immunocytochemistry using the anti-MOMP mAb was done on THP-1 cells after culture with brain homogenates. Cells incubated with homogenates of temporal cortex from control brains were negative for C. pneumoniae using the anti-MOMP mAb. THP-1 cells from cultures incubated with homogenates from temporal cortex of AD patients were immunopositive using the same mAb. C. pneumoniae within infected cells also were visualized by transmission EM. Thus, viable C. pneumoniae were present in brain tissue from the late-onset AD patients studied, but not in congruent tissues from non-AD patients. 14 
APOE Allele Types and the Pathobiology of C. pneumoniae
The one well-accepted risk factor for development of late-onset AD is possession of the ε4 allele type at the apolipoprotein E (APOE) locus on chromosome 19. 15 Not all patients bearing this allele type develop AD, but its presence increases risk for disease development several-fold as well as promoting earlier onset and more rapid neurodegeneration. The APOE gene has five allele types, two of which (ε1, ε5) are rare, and three of which (ε2, ε3, ε4) are relatively common. The product of the APOE gene is therefore polymorphic and is important for cholesterol transport both in the central nervous system and the general circulation. 16, 17 Precisely how the product of the ε4 allele type promotes late-onset AD is not understood, although several hypotheses have been advanced including interac- tion with the neuronal cytoskeleton via tau and promotion of Aβ formation. [18] [19] [20] We reasoned that if the APOE ε4 gene product is associated with late-onset AD, and if C. pneumoniae is associated with the same disease, then some relationship might exist between ε4 and the bacterium. We therefore asked whether we could identify any connection between possession of APOE ε4 and pathogenesis by C. pneumoniae in some other, non-AD context. We chose to examine synovial infection with C. pneumoniae since the organism had been identified in the joints of some arthritis patients. 10 DNA prepared from synovial tissue biopsies of a large patient cohort (average age 43 yr) was screened by PCR for C. trachomatis, C. pneumoniae, and other bacteria. APOE genotype was defined for patients in each of 4 groups: those PCRpositive for C. trachomatis only, C. pneumoniae only, other bacteria only, or no bacteria. RT-PCR confirmed APOE expression in synovial tissue. Genotyping showed that patients PCR-negative in all assays, and those positive in the C. trachomatis-only and non-Chlamydia directed assays, showed distributions of the three main APOE allele types (ε2, ε3, ε4) which mirrored those of the general population. 21 In contrast, 68% of patients with synovial C. pneumoniae DNA had a copy of ε4, 22 a rate 4-5 times that of the general population. This observation strongly suggests a role for this gene product in the pathobiology of the organism, strengthening the association between C. pneumoniae and development of late-onset AD. The data may also suggest that possession of the APOE ε4 allele is a surrogate marker for risk of late-onset AD but a direct marker for the pathobiology of C. pneumoniae.
Related Studies from Other Laboratories
Several laboratories have attempted to replicate aspects of the studies outlined above, and these have provided variable results [T3]. The Seattle group was unsuccessful in identifying C. pneumoniae in paraffin embedded brain tissues from 12 confirmed and 13 suspected late-onset AD patients, using PCR and immunohistochemical analyses. 23 A similar study from a German group also could not identify the organism in any of 20 paraffin embedded AD brain samples, again using PCR and immunohistochemistry. 24 In a third study from California, multiple samples from each of 15 confirmed AD and 5 non-AD control brains were screened by PCR, and each sample was assayed independently several times. 25 Samples were prepared from frozen, rather than paraffin embedded, brain tissues, and culture of the organism from some samples was attempted. The latter analyses were negative for all samples studied, but a small number of weak positives were obtained in the PCR analyses. In all these studies, the authors concluded that the presence of C. pneumoniae in the AD brain could not be confirmed, 23, 24 or that the association between organism and the late-onset AD brain was neither strong nor unique. 25 Recovery of usable amplification template from paraffin embedded tissue is often unreliable, and this may explain in part the PCR-negative results from two of the studies cited above; indeed, this is the reason that only frozen brain tissue samples have been used in all our studies. However, it is difficult to understand why the paraffin embedded tissue samples used in the other studies were negative in immunohistochemical analyses since a Dutch group reported success in identifying C. pneumoniae by 
T3
this method in 11 of 12 paraffin embedded AD brain samples. 26 All control samples were negative for the organism in this study, including several from patients with neurologic diseases other than AD. In our own work, the negative immunohistochemical studies, and in the positive Dutch study, the same or similar mAb targeting the organisms' MOMP or LPS were employed. This suggests differences in technique as a limiting factor in obtaining positive results. Yet another recent report from a Canadian group 27 provides insight into the mostly negative PCR data from the California study. This study used replicate PCR assays and probit regression analyses to show that DNA prepared from up to 85% of the frozen AD brain samples analyzed were PCR-positive for C. pneumoniae if enough replicates were performed; multiply assayed controls were always PCR-negative. Replicate PCR assays targeting C. pneumoniae have also been shown to be required for identification of this organism in peripheral blood mononuclear cells and nasopharyngeal samples. 28 Another study indicated that for certain PCR systems targeting the hepatitis C viral genome, replicate assays and probit regression analysis are useful. 29 These data indicate that C. pneumoniae load in the AD brain and elsewhere can be extremely low, and thus identification of chlamydial DNA in preparations from such materials requires not only careful template preparation but also repetitive analyses.
Additional Data Supporting an Association Between C. pneumoniae and Late-onset Alzheimer's Disease
In our original study, three non-AD control brain samples assessed by PCR for C. pneumoniae DNA were derived from patients with multiple sclerosis (MS) 14 and all were negative. Recently we extended PCR screening assays to frozen brain tissue samples from patients with Parkinson's disease (PD) and additional controls. DNA samples from temporal cortex and hippocampus were assayed from three non-AD/non-PD control individuals, three patients with PD, and two patients with both PD and AD. In multiple PCR assays targeting the C. pneumoniae 16S rRNA gene, the gene encoding MOMP, and other genes, each sample from controls was negative, as were all samples from the PD patients. However, samples from each patient with PD plus AD were PCR-positive for C. pneumoniae. Further, we have obtained frozen tissue samples from temporal cortex, hippocampus, and other brain regions from nine additional confirmed AD patients and several controls. Multiple PCR assays targeting three C. pneumoniae genes were negative for all controls but positive for 8 of the 9 AD patients. We have also begun analyses of mRNA production from the βAPP, PS-1, PS-2, and several other ADrelevant host genes in C. pneumoniae-infected and control astrocytoma cell lines (APOE ε4-bearing and -lacking). Our initial data suggest that infection with the organism alters host production of mRNA encoding these proteins in this cell type, especially in those cells bearing a copy of the APOE ε4 allele.
Conclusions
Several earlier studies attempted to define an etiologic relationship between infection with various viruses or bacteria and development of late-onset AD, but no such link has been demonstrated as yet. The observations reviewed here from our initial study and those from two confirming studies argue that C. pneumoniae is present and viable in the AD brain, and that the organism is present primarily in regions of characteristic neuropathology. While much work remains, including providing full explanation for the several studies unable to find the organism in AD brain samples, these results seem to be the first to demonstrate consistent proximity of a known bacterial pathogen to regions of standard AD-related neuropathology. It is important that the organism was identified only in AD brain materials and not in congruent brain samples from patients with MS or PD or from patients without neurologic disease. However, the number of samples assayed from patients with MS and PD in my laboratory and others so far is small. Further assessment of C. pneumoniae in brain from patients with other neurodegenerative diseases is required. It is also critically important for other laboratories to replicate the PCR, immunohistochemistry, EM, and IEM observations in larger AD and control patient populations.
Assuming that C. pneumoniae is indeed present in the late-onset AD brain but not those of normal individuals or patients with other neurologic diseases, such an association does not constitute a demonstration that the organism actually causes the disease. C. pneumoniae is a capable opportunistic pathogen, and it is possible, perhaps even likely, that it takes up residence in the AD brain in infected individuals only after the initiation of relevant neuropathology by some other means. All species of Chlamydia are known to cause inflammation at sites of their residence, and data from many studies indicate that treatment of AD patients with anti-inflammatory drugs is beneficial. 30 This observation suggests that the inflammation which characterizes the AD brain is an important component of neuropathogenesis. Thus, whether C. pneumoniae actually initiates the neurodegeneration process in late-onset AD or not, it seems probable that some portion of the AD-related inflammation is attributable to chlamydial infection.
We do not know at what point, by what means, or under what physiologic conditions the organism reaches the central nervous system in susceptible individuals. It seems unlikely that it does so solely as a result of normal aging processes since virtually none of our or others' age-matched control patients was positive for the organism. Moreover, the organism does not appear to be present in brain tissues from individuals with neurodegenerative diseases other than late-onset AD. Another issue of importance will be to determine whether C. pneumoniae infecting AD brain tissues represents a specific neurotropic strain. All these questions must be major foci of future research in this area. Moreover, given the demonstrated beneficial effect of anti-inflammatory drugs on lateonset AD patients, more study of these and related compounds may prove to be useful therapeutically for AD patients. Use of antibiotic and other anti-Chlamydia pneumoniae compounds in late-onset AD patients may also be useful, and trials to examine efficacy of such treatment regimens are now underway in a limited manner in some laboratories.
